Applying a Novel Approach to Modulating
NMDA Receptors to Develop Improved CNS Therapies

• Overview:

• Naurex has discovered a novel way of modulating NMDA receptors via a new mechanism of action called Glycine-site Functional Partial Agonists (GFPAs), which are designed to achieve the strong efficacy of classic NMDA modulators without their limiting CNS side effects
  
  

  Learn more… 

• Our Mission:

• Naurex is developing its novel GFPA drug platform and programs to treat multiple CNS diseases including depression, cognitive disorders, schizophrenia and neuropathic pain.
  
  First clinical target:  Treatment-resistant depression
  
  

  Learn more…